Genitourinary Cancer
News
Certain refractory prostate cancers respond to olaparib
Key clinical point: Olaparib induced a 33% response rate in refractory, progressing prostate cancers in a phase II trial.
News
Urinary biomarkers miss the mark for bladder cancer
Key clinical point:Urinary biomarkers used alone miss a substantial proportion of patients with bladder cancer and are subject to false-positive...
News
Blacks receive inferior care for localized prostate cancer
Key clinical point: Compared with whites, black patients with localized prostate cancer received lower quality of care. Major finding: Blacks...
Original Report
The value of anticancer drugs in metastatic castrate-resistant prostate cancer: economic tools for the community oncologist
News
Self-assessed mental health scores tied to radical cystectomy complications
Measuring baseline mental health before surgery may provide additional information that can improve the risk stratification of patients undergoing...
Video
VIDEO: Long-term responses possible in advanced kidney cancer?
News
Prostate cancer: Men with comorbidity may be better off with no ADT
Key clinical point: Forgoing androgen deprivation therapy cuts rather than raises overall and cardiac mortality in certain patients with prostate...
News
No survival difference between continuous and intermittent ADT
Key clinical point: Intermittent androgen deprivation is not inferior to continuous therapy in regards to overall survival.
News
Noncanonical Wnt signaling implicated in antiandrogen-resistant prostate cancer
Key clinical point: Noncanonical Wnt signaling was significantly enriched in single circulating tumor cells (CTCs) from patients resistant to the...
News
Individualized approach improves surveillance after renal cell carcinoma resection
Key clinical point: An individualized approach to surveillance after surgical resection in patients with renal cell carcinoma may provide better...
News
Low-risk prostate cancer: Replace immediate intervention with immediate contemplation
Key clinical point: Men with favorable-risk prostate cancer have a low risk of progression to a lethal phenotype and should consider active...